GnRH Agonists in the Treatment of Endometriosis

  • Ricardo Serta


Endometriosis is present in approximately 5 to 7% of reproductive age women and is believed to cause infertility in 20 to 40% of those affected. There is some evidence supporting a hormone-dependent mechanism for endometriosis, as it is rarely found prior to or beyond reproductive age. Furthermore, it regresses following bilateral oophorectomy. Although definitive treatment can best be accomplished by surgery, the potential need for repetitive operative procedures and the inability to remove all endometrial implants at the time of surgery have resulted in the introduction of several types of medical treatment, including progestogens, estrogen-progestogen combinations, and danazol. In recent years gonadotropin-releasing hormone agonists (GnRHa) have experienced enormous popularity for the medical treatment of endometriosis.


GnRH Agonist Endometriosis Patient American Fertility Society GnRHa Therapy Nafarelin Acetate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Seibel MM. Infertility A Comprehensive Text. Norwalk: Appleton amp Lange, 1990: 122.Google Scholar
  2. 2.
    Shaw RW. Rationale in use of LHRH analogues in endometriosis. Horm Res 1989; 32 (Suppl 1): 110.PubMedCrossRefGoogle Scholar
  3. 3.
    Furr BJA. Pharmacology of the luteinizing hormone-releasing hormone (LHRH) analogue, Zoladex. Horm Res 1989; 32 (Suppl 1): 86.PubMedCrossRefGoogle Scholar
  4. 4.
    Dupont A, Dupont P, Belanger A, et al. Hormonal and biochemical changes during treatment of endometriosis with luteinizing hormone-releasing hormone (LHRH) agonist (D-Trp6,des-Gly-NH210) LHRH ethylamide. Fertil Steril 1990; 54: 227.PubMedGoogle Scholar
  5. 5.
    Dlugi AM, Rufo S, D’Amico JF, Seibel MM: A comparision of buserelin versus danazol on plasma lipids. Fertil Steril 1988; 49: 913.PubMedGoogle Scholar
  6. 6.
    Miller NE. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 1987; 113: 589.PubMedCrossRefGoogle Scholar
  7. 7.
    Crook D, Gardner R, Worthington M, et al. Zoladex versus Danazol in the treatment of pelvic endometriosis: Effects on plasma lipid risk factors. Horm Res 1989; 32 (Suppl 1): 157.PubMedCrossRefGoogle Scholar
  8. 8.
    Gordon T, Castelli WP, Hjortland MC, et al. High density lipoproteins as a protective factor against coronary heart disease. Am J Med 1977; 62: 707.PubMedCrossRefGoogle Scholar
  9. 9.
    Devogelaer J-P, Nagant de Deuxchaisnes C, Donnez J, et al. LHRH analogues and bone loss. Lancet 1987; 1: 1498.PubMedCrossRefGoogle Scholar
  10. 10.
    Matta WH, Shaw RW, Hesp R, et al. Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue buserelin in premenopausal women. Clin Endocrinol 1988; 29: 45.CrossRefGoogle Scholar
  11. 11.
    Cann CE, Henzl M, Burry K, et al. Reversible bone loss is induced by GnRH agonists. Endocrine Society 68th Annual Meeting. Program and Abstracts, 1986, p. 24.Google Scholar
  12. 12.
    Stevenson JC, Lees B, Gardner R, et al. A comparison of the skeletal effects of Goserelin and Danazol in premenopausal women with endometriosis. Horm Res 1989; 32 (Suppl 1): 161.PubMedCrossRefGoogle Scholar
  13. 13.
    Johansen JS, Riis BJ, Hassager C, et al. The effect of a gonadotropin-releasing hormone agonist (Nafarelin) on bone metabolism. J Clin Endocrinol Metab 1988; 67: 701.PubMedCrossRefGoogle Scholar
  14. 14.
    Dlugi AM, Miller JD, Knittle J, et al. Lupron depot (Leuprolide acetate for depot suspension) in the treatment of endometriosis: A randomized, placebo-controlled, double-blind study. Fertil Steril 1990; 53: 419.Google Scholar
  15. 15.
    Surrey ES, Gambone JC, Lu JKH, et al. The effects of combining norethindrone with a gonadotropin-releasing hormone agonist in the treatment of symptomatic endometriosis. Fertil Steril 1990; 53: 620.PubMedGoogle Scholar
  16. 16.
    Barnes RB, Mercer LJ, Montner S. Characteristics of bone loss during treatment with a depot gonadotropin-releasing hormone agonist (GnRH-a). Abstract Presented at the 44th Annual Meeting of The American Fertility Society, Atlanta, GA, October 10-13, 1988; p. 23.Google Scholar
  17. 17.
    Dmowski WP, Radwanska E, Binor Z, et al. Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: A randomized, comparative study. Fertil Steril 1989; 51: 395.PubMedGoogle Scholar
  18. 18.
    Buhler K, Schindler AE. Long-term follow-up of patients treated for endometriosis with LHRH analogue buserelin. In: Brosens I, Jacobs HS, Runnenbaun B, eds LHRH Ana-logues in Gynecology. Park Ridge, New Jersey: The Parthenon Publishing Group, 1990: 159.Google Scholar
  19. 19.
    Donnez J, Nisolle M, Clerckx F, et al. The ovarian endometrial cyst: The combined (hormonal and surgical) therapy. In: Brosens I, Jacobs HS, Runnenbaun B, eds LHRH Ana-logues in Gynecology. Park Ridge, New Jersey: The Parthenon Publishing Group, 1990: 165.Google Scholar
  20. 20.
    American Fertility Society: Revised American Fertility Society Classification of Endometriosis. Fertil Steril 1985; 43: 351.Google Scholar
  21. 21.
    Steingold KA, Cedars M, Lu JKH, et al. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist. Obstet Gynecol 1987; 69: 403.PubMedGoogle Scholar
  22. 22.
    Kennedy SH, Williams IA, Brodribb J, et al. A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertil Steril 1990; 53: 998.PubMedGoogle Scholar
  23. 23.
    Franssen AMHW, Kauer FM, Chadha DR, et al. Endometriosis: Treatment with gonadotropin-releasing hormone agonist Buserelin. Fertil Steril 1989; 51: 401.PubMedGoogle Scholar
  24. 24.
    Evers JLH. The second look laparoscopy for evaluation of the result of medical treatment of endometriosis should not be performed during ovarian suppression. Fertil Steril 1987; 47: 502.PubMedGoogle Scholar
  25. 25.
    Schriock E, Monroe SE, Henzl M, et al. Treat-ment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin). Fertil Steril 1985; 44: 583.PubMedGoogle Scholar
  26. 26.
    Tummon IS, Pepping ME, Binor Z, et al. A randomized prospective comparision of endocrine changes induced with intranasal Leuprolide or danazol for endometriosis. Fertil Steril 1989; 51: 390.PubMedGoogle Scholar
  27. 27.
    Fraser HM, Sandow J, Co wen GM, et al. Long term suppression of ovarian function by a luteinizing-hormone releasing hormone agonist implant in patients with endometriosis. Fertil Steril 1990; 53: 61.PubMedGoogle Scholar
  28. 28.
    Zorn JR, Mathieson J, Risquez F, et al. Treatment of endometriosis with a delayed release preparation of the agonist D-Trp6 -luteinizing hormone-releasing hormone: Long term follow- up in a series of 50 patients. Fertil Steril 1990; 53: 401.PubMedGoogle Scholar
  29. 29.
    Henzl MR, Corson SL, Moghissi K, et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis. N Engl J Med 1988; 318: 485.PubMedCrossRefGoogle Scholar
  30. 30.
    Lemay A, Maheux R, Faure N, et al. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (buserelin) as a new therapeutic approach for endometriosis. Fertil Steril 1984; 41: 863.PubMedGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1993

Authors and Affiliations

  • Ricardo Serta

There are no affiliations available

Personalised recommendations